コンテンツへスキップ
Merck
  • Subclinical epileptiform activity in children with electrical status epilepticus during sleep: effects on cognition and behavior before and after treatment with levetiracetam.

Subclinical epileptiform activity in children with electrical status epilepticus during sleep: effects on cognition and behavior before and after treatment with levetiracetam.

Epilepsy & behavior : E&B (2013-02-05)
Helge Bjørnæs, Kristin A Bakke, Pål Gunnar Larsson, Einar Heminghyt, Elisif Rytter, Line M Brager-Larsen, Ann-Sofie Eriksson
要旨

We performed a double-blind placebo-controlled crossover study of the effects of spike activity during sleep and when awake on learning, long-term memory, vigilance and behavior before and after treatment with levetiracetam in children with electrical status epilepticus during sleep. At baseline, verbal learning declined with increasing spike activity, but there were no relations between spike activity and memory, vigilance or behavior. Levetiracetam was effective in reducing sleep-related spike activity, but on a group level, this had no clear effects on behavior, vigilance or learning and memory. Our results do not allow firm conclusions whether to treat nocturnal epileptiform activity or not; larger samples and longer follow-up may be needed.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ピラセタム
Sigma-Aldrich
レベチラセタム, ≥98% (HPLC)
Supelco
レベチラセタム 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
レベチラセタム, European Pharmacopoeia (EP) Reference Standard
Levetiracetam impurity D, European Pharmacopoeia (EP) Reference Standard